THIS BLOG WILL CURE WORLD FROM AIDS.

1.One out of four persons in India has responded favourably to the phase one trial of an HIV/AIDS vaccine, experts said here today. The preliminary results of the vaccine trial showed that among 25 per cent of volunteers, an immune response was triggered, said Dr Jean-Louis Excler, Senior Medical Director of International Aids Vaccine initiative, a global body that works for development of a vaccine against the disease.

2."Twenty-five per cent of the volunteers showed immune response when given high doses of the vaccine," he said at a workshop here.

3.The phase one trial of Tgaaco9 Vaccine (RAAV), which was conducted in National Aids Research Institute (NARI), Pune, in collaboration with Indian Council For Medical Research (ICMR), National Aids Control Organisation (NACO) and IAVI, got over last year.

4.As per him it was "confusing to see that the higher the dose, the higher the response to the vaccine." He said that they want to come out of with the right dosage which is safe, feasible and that could be manufactured in a large scale.

5.According to IAVI Medical Director Dr Sonali Kochhar, they are considering to start a trial of a "dual vaccine" that would be more effective. "We want to conduct the prime boost trial using three vaccine combination. We will be filling application for starting the trial before the regulatory authorities," said Kochhar, adding it could only be by the end of this year or the beginning of the next year. The three combination vaccine would be RAAV, the ongoing Chennai-based trial of modified vaccine Ankara (MVA) and DNA vaccine which is being conducted in Africa.